Evolus (NASDAQ:EOLS) Reaches New 52-Week Low - Should You Sell?

Evolus, Inc. (NASDAQ:EOLS - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $10.16 and last traded at $10.21, with a volume of 505260 shares changing hands. The stock had previously closed at $10.74.

Analyst Ratings Changes

EOLS has been the topic of a number of research reports. Barclays upped their price target on shares of Evolus from $16.00 to $20.00 and gave the stock an "overweight" rating in a research note on Friday, September 13th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 target price on shares of Evolus in a research report on Friday, September 13th. HC Wainwright reiterated a "buy" rating and set a $27.00 price target on shares of Evolus in a report on Thursday, November 7th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Evolus in a report on Monday, September 16th.

Evolus Trading Down 4.9 %

The company has a fifty day simple moving average of $12.50 and a two-hundred day simple moving average of $13.74. The company has a market capitalization of $646.51 million, a P/E ratio of -11.22 and a beta of 1.32. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.

Institutional Trading of Evolus

A number of institutional investors and hedge funds have recently modified their holdings of the company. Essex Investment Management Co. LLC lifted its position in shares of Evolus by 0.4% in the 3rd quarter. Essex Investment Management Co. LLC now owns 295,553 shares of the company's stock worth $4,788,000 after acquiring an additional 1,111 shares during the period. Arizona State Retirement System lifted its position in Evolus by 9.4% in the second quarter. Arizona State Retirement System now owns 14,603 shares of the company's stock worth $158,000 after purchasing an additional 1,253 shares during the period. Creative Planning boosted its stake in Evolus by 23.7% during the third quarter. Creative Planning now owns 15,451 shares of the company's stock worth $250,000 after buying an additional 2,963 shares in the last quarter. Sei Investments Co. increased its holdings in Evolus by 9.8% in the 2nd quarter. Sei Investments Co. now owns 33,802 shares of the company's stock valued at $367,000 after buying an additional 3,020 shares during the period. Finally, Quest Partners LLC bought a new stake in Evolus in the 2nd quarter valued at $43,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.